Deferiprone as an oral iron chelator in sickle cell disease
Ersi Voskaridou(Laiko General Hospital of Athens), Dimitris Loukopoulos(Biomedical Research Foundation of the Academy of Athens), Akis Ourailidis, Ioannis Papassotiriou(National and Kapodistrian University of Athens), Maroussa Douskou, John Meletis(Athens State University), Evangelos Terpos(National and Kapodistrian University of Athens), Alexandra Stamoulakatou(Children's Hospital Agia Sophia)
Cited by 36
Related Papers
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493
Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
|Journal of Clinical Oncology|2010|409
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
|Leukemia|2017|356
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320